AbbVie (ABBV) said Friday it received approval from the US Food and Drug Administration for its antibiotic Emblaveo for the treatment of adults with complicated intra-abdominal infections.
The approval covers Emblaveo's use with metronidazole in patients who have limited or no alternative options to treat their infections, including those caused by Gram-negative bacteria which can become antimicrobial resistant, the drugmaker said.
Emblaveo will be available for commercial use in Q3, AbbVie said.
Price: 191.52, Change: -1.45, Percent Change: -0.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.